BERLIN — Re-treatment with an anti-epidermal growth factor receptor (EGFR) agent is effective in patients with chemorefractory metastatic colorectal cancer (mCRC) with RAS and BRAF wild-type tumors ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈